JP2023523241A5 - - Google Patents

Info

Publication number
JP2023523241A5
JP2023523241A5 JP2022564258A JP2022564258A JP2023523241A5 JP 2023523241 A5 JP2023523241 A5 JP 2023523241A5 JP 2022564258 A JP2022564258 A JP 2022564258A JP 2022564258 A JP2022564258 A JP 2022564258A JP 2023523241 A5 JP2023523241 A5 JP 2023523241A5
Authority
JP
Japan
Prior art keywords
alkyl
pharmaceutically acceptable
acceptable salt
compound according
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022564258A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023523241A (ja
JP7830347B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/028323 external-priority patent/WO2021216656A1/en
Publication of JP2023523241A publication Critical patent/JP2023523241A/ja
Publication of JP2023523241A5 publication Critical patent/JP2023523241A5/ja
Priority to JP2025156540A priority Critical patent/JP2025186437A/ja
Application granted granted Critical
Publication of JP7830347B2 publication Critical patent/JP7830347B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022564258A 2020-04-22 2021-04-21 Hbvの処置のための5員のヘテロアリールカルボキサミド化合物 Active JP7830347B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025156540A JP2025186437A (ja) 2020-04-22 2025-09-19 Hbvの処置のための5員のヘテロアリールカルボキサミド化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063014001P 2020-04-22 2020-04-22
US63/014,001 2020-04-22
PCT/US2021/028323 WO2021216656A1 (en) 2020-04-22 2021-04-21 5-membered heteroaryl carboxamide compounds for treatment of hbv

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025156540A Division JP2025186437A (ja) 2020-04-22 2025-09-19 Hbvの処置のための5員のヘテロアリールカルボキサミド化合物

Publications (3)

Publication Number Publication Date
JP2023523241A JP2023523241A (ja) 2023-06-02
JP2023523241A5 true JP2023523241A5 (cg-RX-API-DMAC10.html) 2024-05-02
JP7830347B2 JP7830347B2 (ja) 2026-03-16

Family

ID=75919388

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022564258A Active JP7830347B2 (ja) 2020-04-22 2021-04-21 Hbvの処置のための5員のヘテロアリールカルボキサミド化合物
JP2025156540A Pending JP2025186437A (ja) 2020-04-22 2025-09-19 Hbvの処置のための5員のヘテロアリールカルボキサミド化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025156540A Pending JP2025186437A (ja) 2020-04-22 2025-09-19 Hbvの処置のための5員のヘテロアリールカルボキサミド化合物

Country Status (14)

Country Link
US (1) US12655130B2 (cg-RX-API-DMAC10.html)
EP (1) EP4139292A1 (cg-RX-API-DMAC10.html)
JP (2) JP7830347B2 (cg-RX-API-DMAC10.html)
KR (1) KR20230005881A (cg-RX-API-DMAC10.html)
CN (3) CN122167357A (cg-RX-API-DMAC10.html)
AR (1) AR121905A1 (cg-RX-API-DMAC10.html)
AU (2) AU2021261307B2 (cg-RX-API-DMAC10.html)
BR (1) BR112022021419A2 (cg-RX-API-DMAC10.html)
CA (1) CA3180706A1 (cg-RX-API-DMAC10.html)
IL (1) IL297305B1 (cg-RX-API-DMAC10.html)
MX (2) MX2022013251A (cg-RX-API-DMAC10.html)
PH (1) PH12022552815A1 (cg-RX-API-DMAC10.html)
TW (1) TW202206415A (cg-RX-API-DMAC10.html)
WO (1) WO2021216656A1 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240089748A (ko) * 2021-10-20 2024-06-20 어셈블리 바이오사이언시스, 인크. 방법
JP2024541124A (ja) * 2021-10-20 2024-11-06 アセンブリー・バイオサイエンシーズ・インコーポレイテッド 新規結晶形態
WO2023069544A1 (en) * 2021-10-20 2023-04-27 Assembly Biosciences, Inc. 5-membered heteroaryl carboxamide compounds for treatment of hbv
WO2023069545A1 (en) * 2021-10-20 2023-04-27 Assembly Biosciences, Inc. 5-membered heteroaryl carboxamide compounds for treatment of hbv
WO2023069547A1 (en) * 2021-10-20 2023-04-27 Assembly Biosciences, Inc. 5-membered heteroaryl carboxamide compounds for treatment of hbv
EP4448492B1 (en) 2021-12-17 2026-03-04 Reglagene, Inc. Compositions and methods of making and using small molecules in the treatment of cancer
JP7894535B2 (ja) 2023-02-28 2026-07-23 レグラジーン、インコーポレイテッド 健康状態の治療のための小分子を作製および使用するための組成物および方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013006394A1 (en) 2011-07-01 2013-01-10 Institute For Hepatitis And Virus Research Sulfamoylbenzamide derivatives as antiviral agents against hbv infection
US9968650B2 (en) 2011-07-13 2018-05-15 Indiana University Research And Technology Corporation Modified viral structural protein with antiviral activity
AR089671A1 (es) 2012-01-06 2014-09-10 Janssen R & D Ireland 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
CA2881057C (en) 2012-08-28 2020-10-27 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
NZ704758A (en) 2012-08-28 2018-06-29 Janssen Sciences Ireland Uc Fused bicyclic sulfamoyl derivatives and the use thereof as medicaments for the treatment of hepatitis b
CA2881322A1 (en) 2012-09-10 2014-03-13 F. Hoffmann-La Roche Ag 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
HK1215030A1 (zh) 2012-11-09 2016-08-12 Indiana University Research And Technology Corporation 用於hbv組裝效應劑的替代用途
CN104918612B (zh) 2012-12-06 2019-10-25 巴鲁克斯布隆伯格研究所 作为抗hbv感染的抗病毒剂的官能化苯甲酰胺衍生物
HK1217649A1 (zh) 2012-12-27 2017-01-20 德雷克塞尔大学 針對hbv感染的新型抗病毒劑
JP6466348B2 (ja) 2013-02-28 2019-02-06 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー スルファモイル−アリールアミドおよびb型肝炎を処置するための医薬品としてのその使用
HUE033542T2 (en) 2013-04-03 2017-12-28 Janssen Sciences Ireland Uc Their use as medicaments for the treatment of N-phenylcarboxamide derivatives and hepatitis B
TW202126620A (zh) 2013-05-17 2021-07-16 愛爾蘭商健生科學愛爾蘭無限公司 胺磺醯基吡咯醯胺衍生物及其作為用於治療b型肝炎藥物的用途
HUE040446T2 (hu) * 2013-05-17 2019-03-28 Janssen Sciences Ireland Uc Szulfamoiltiofenamid-származékok és gyógyszerként történõ alkalmazásuk hepatitis B kezelésére
PE20151951A1 (es) 2013-05-17 2015-12-26 Hoffmann La Roche Heteroarildihidropirimidinas unidas por puentes en 6 para el tratamiento y la profilaxis de infeccion por el virus de la hepatitis b
WO2015011281A1 (en) * 2013-07-25 2015-01-29 Janssen R&D Ireland Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
ES2748029T3 (es) * 2014-03-13 2020-03-12 Univ Indiana Res & Tech Corp Moduladores alostéricos de proteína núcleo de hepatitis B
TWI730985B (zh) * 2015-09-15 2021-06-21 美商艾森伯利生物科學公司 B型肝炎核心蛋白質調節劑
KR102398439B1 (ko) * 2016-03-07 2022-05-16 이난타 파마슈티칼스, 인코포레이티드 B형 간염 항바이러스제
TW201806956A (zh) * 2016-06-29 2018-03-01 諾維拉治療公司 二氮呯酮衍生物及治療b型肝炎感染之方法
AU2017326356A1 (en) * 2016-09-15 2019-04-11 Assembly Biosciences, Inc. Hepatitis B core protein modulators
WO2019076358A1 (en) 2017-10-19 2019-04-25 Js Innopharm (Shanghai) Ltd HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF
SG11202104086PA (en) * 2018-10-22 2021-05-28 Assembly Biosciences Inc 5-membered heteroaryl carboxamide compounds for treatment of hbv
WO2021216660A1 (en) * 2020-04-22 2021-10-28 Assembly Biosciences, Inc. 5-membered heteroaryl carboxamide compounds for treatment of hbv

Similar Documents

Publication Publication Date Title
JP2022508953A5 (cg-RX-API-DMAC10.html)
JP2017537949A5 (cg-RX-API-DMAC10.html)
RU2395500C2 (ru) 2,4-пиримидиндиамины, применяемые в лечении неопластических болезней, воспалительных и иммунных расстройств
RU2348617C2 (ru) Производные 2-пиридона в качестве ингибиторов эластазы нейтрофилов и их применение
JP2013523614A5 (cg-RX-API-DMAC10.html)
JP2009512719A5 (cg-RX-API-DMAC10.html)
US20080182845A1 (en) Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
JP2005532389A5 (cg-RX-API-DMAC10.html)
JP2006506443A5 (cg-RX-API-DMAC10.html)
JP2008510771A5 (cg-RX-API-DMAC10.html)
JP2007532479A5 (cg-RX-API-DMAC10.html)
RU2007123235A (ru) Противоопухолевые соединения
JP2017523169A5 (cg-RX-API-DMAC10.html)
JP2015526468A5 (cg-RX-API-DMAC10.html)
JP2009542716A5 (cg-RX-API-DMAC10.html)
RU2007116119A (ru) Производные циклоспорина, замещенные 3-эфиром и 3-тиоэфиром, для лечения и профилактики инфекционного гепатита с
JP2015504081A5 (cg-RX-API-DMAC10.html)
RU2015110082A (ru) Соединения дигидропиримидина и их применение в фармацевтических препаратах
JP2014500296A5 (cg-RX-API-DMAC10.html)
JP2011529964A5 (cg-RX-API-DMAC10.html)
JP2008508214A (ja) 女性の性障害の治療用ピペラジン誘導体
JP2019527724A5 (cg-RX-API-DMAC10.html)
RU2017105902A (ru) Соединения для применения в дегельминтизации
JP2020511536A5 (cg-RX-API-DMAC10.html)
JP2010521483A5 (cg-RX-API-DMAC10.html)